INdustrycTceh INsight Logo

Pfizer plans to file for full FDA approval of the Covid vaccine

Pfizer plans to file for full FDA approval of the Covid vaccine

May 5, 2021: -On Tuesday, Pfizer said it plans to file for full U.S. approval of its Covid-19 vaccine with German drugmaker BioNTech at this month-end. The company will be able to market the shot directly to consumers if the company signs off.

According to Pfizer, first-quarter sales of its Covid-19 vaccine was $3.5 billion, nearly 24% of its revenue for the quarter in its earnings report. It reported earnings and revenue were over Wall Street’s expectations.

The company expects full-year sales of $26 billion from the vaccine, up from its last forecast of nearly $15 billion. An adjusted pretax profit in the high 20% range of revenue for the vaccine is expected.

According to the earnings report, revenue from Pfizer’s oncology, internal medicine, hospital, and rare disease units rose by double digits during the quarter. The company’s inflammation and immunology unit generated around $1 billion in sales, a 9% rise from the previous year.

The company received U.S. approval of its Covid vaccine in December. Pfizer distributed millions of doses to the U.S. since then, intending to deliver 300 million doses by July-end.

Usually, it takes the Food and Drug Administration almost a year or more than that to determine if a drug is safe and effective for use in the general public. Due to the coronavirus pandemic, which has killed nearly 600,000 people in the United States, the FDA permitted using the shots under an Emergency Use Authorization.

The authorization permits conditional approval depending on two months of data. It’s not the same as a Biologic License Application, in which six months of data and secures full support is needed.

According to a slide presentation that accompanied the earnings release of the company, the company also said it is expecting to apply for a EUA for a booster shot that could protect against Covid variants in late July. It intends to apply for authorization for its vaccine for use in younger children in September and infants in November.

On April 1, Pfizer and BioNTech made an announcement that new data from their clinical trial showed their two-dose vaccine was safe and over 91% effective after the second dose.

At the time, Pfizer CEO Albert Bourla said the new data positions the companies “to submit a Biologics License Application to the U.S. FDA.”

If the vaccine is approved fully, it sets the stage for Pfizer and BioNTech to start advertising the shots directly to consumers and change the prices. It also allows the shots to stay on the market once the pandemic is over and the U.S. is no longer considered an “emergency.”

About Us

We provide the insights on leaders who are responsible for taking their organization to new heights, all the while bringing together a group of talented individuals.

Recent Posts

The Lake Companies | Making Manufacturing Easier…Forever! | Greg Lake

Today, most manufacturing companies face similar challenges. Those tend to intertwine themselves with implementing and adhering to best business practices. There are many reasons for this, including:
No standard definition for best practices.
The unending confusion of new shiny objects created by the technology industry.
The fact that manufacturing is such a complex industry.

Cyncly | Preparing Customers for the Future | Andrea Gnoato

Cyncly was created in September of 2022 as the new brand to unite Compusoft, 2020, and their affiliate companies after the two companies merged in 2021. One of the key factors driving the decision to form Cyncly as a global brand was that consumers worldwide wanted a seamless experience when they decided to improve their homes.

Tecnomatix | Making Transformative Products | Tony Hemmelgarn

Tecnomatix® is a comprehensive portfolio of digital manufacturing solutions that helps companies to digitalize manufacturing and the process of turning innovative ideas and raw materials into transformative products. It is a software suite that enables organizations to create a digital twin of their manufacturing processes, including robots, automation, material handling systems, and people, to improve the performance of their business.